Smileyscope Secures $10.74M Seed Round to Revolutionize VR-Enabled Patient Care

Smileyscope, a multi-award winning digital therapeutics company, is proud to announce that it has successfully raised $10,740,000 in its latest funding round. This achievement marks an important milestone for the company as it continues its mission to expand the frontiers of patient-centered care. With its proprietary technology, Smileyscope has revolutionized the way medical procedures are experienced by framing them as choreographed virtual-reality (VR) sessions. These clinically proven, regulatory body-approved VR experiences significantly reduce patient pain, anxiety, and even the need for restraints during various procedures—from needle applications and wound dressings to anaesthetic induction and plaster cast management. The significant investment will be dedicated to further refining Smileyscope VR, enhancing its integration into clinical workflows, and broadening its availability across the globe. Designed by clinicians, for clinicians, the product has already transformed the patient experience in leading hospitals in Australia, the USA, and the UAE, garnering heartfelt endorsements from medical professionals and families alike. One anaesthetist recently remarked that the system is a “game changer,” noting how it leads to less reliance on sedation and pain medication, while a parent shared how Smileyscope made a difference in easing a child’s distress during procedures. Such testimonials reflect the company’s vision to improve the moments that matter most. As Smileyscope steps into its next phase of growth—expanding its presence in the USA, UAE, Europe, and the UK—this latest funding round will be pivotal in driving innovation, research, and development, cementing its status as a leader in digital therapeutics and a beacon of hope for enhancing patient care worldwide.